



## SYNTHESIS AND BIOLOGICAL ACTIVITY OF 2- SUBSTITUTED THIOHYDANTOIN

**Sanjay V. Kolhe**

P. G. Department of chemistry  
Shri Shivaji Arts', Commerce & Science College, Akot Dist. Akola  
Email; -drsanjaykolhe22@gmail.com

### ABSTRACT:

2 hydroxy substituted calcone (I a-d) was dissolved in DMSO and mercuric acetate was added to it. The reaction mixture was refluxed for 2-3 hours and then diluted with water. The solid separated was crystallized from rectified spirit to give coumarone 3-one i.e. aurone (II a-d). Substituted aurone further refluxed with thiourea in ethanolic KOH for 3 hours gives substituted thiohydantoin. The structural elucidation of compound was done on the basis of analytical and spectral data.

**Key words:** Synthesis, coumarone 3-one, mercuric acetate, urea, ethanolic KOH, antimicrobial activity.

### INTRODUCTION:

Thiohydantoin derivatives are sulfur analogs of hydantoin derivatives with one or both carbonyl groups replaced by thiocarbonyl groups<sup>1</sup>. Among the known thiohydantoin derivatives, 2-thiohydantoin derivatives are most notably known due of their wide applications as hypolipidemic<sup>2</sup>, anticarcinogenic<sup>3</sup>, antimutagenic<sup>4</sup>, antithyroidal<sup>5</sup>, antiviral (e.g., against herpes simplex virus, HSV)<sup>6</sup>, human immunodeficiency virus (HIV)<sup>7</sup> and tuberculosis<sup>8</sup>, antimicrobial (antifungal and antibacterial)<sup>9</sup>, anti-ulcer and anti-inflammatory agents<sup>10</sup>, as well as pesticides<sup>11</sup>. Additionally, 2-thiohydantoin derivatives have been used as reference standards for the development of C-terminal protein sequencing<sup>12</sup>, as reagents for the development of dyes<sup>13</sup> and in textile printing, metal cation complexation and polymerization catalysis<sup>14</sup>. It is therefore not surprising that various different synthetic methods have been developed to prepare 2-thiohydantoin and its derivatives. Some of the most commonly used methods are the treatment of  $\alpha$ -amino acids with acetic anhydride followed by ammonium thiocyanate<sup>15</sup> and the coupling reaction between  $\alpha$ -amino acid derivatives and isothiocyanate<sup>4a,12b,16</sup>. Other preparative methods for 2-thiohydantoin derivatives include the reactions between thiourea and benzil<sup>17</sup> thiourea and  $\alpha$ -halo acids<sup>18</sup>, oxazolinone and thiocyanate<sup>19</sup>, amino amide and diimidazole thiocarbonate<sup>20</sup>, and others<sup>21</sup>. In addition, some of the above reactions have been modified to take place under microwave irradiation<sup>17c</sup> and solid-phase<sup>16a,22</sup> or fluorous-phase<sup>23</sup> supported reaction conditions. However, the above methods often suffer from one or more synthetic limitations for large-scale preparation of 2-thiohydantoin derivatives due to their use of expensive, moisture sensitive and/or highly toxic starting materials and reagents. Moreover, the methods developed for combinatorial synthesis and used to prepare 2-

thiohydantoin derivatives in small quantities for purposes like biological testing may not be feasible when operated on a large scale<sup>22d,24</sup>. A Thiohydantoin derivative has also been reported as herbicidal<sup>25</sup>. Bucherer reaction has also been reported for the synthesis of thiohydantoin<sup>26</sup>. Sulfonylated thiohydantoin derivatives has also been reported as fungicides. Antidiabetic hydantoin derivatives have been synthesized by Japanese scientists<sup>27</sup>. 1-3-diglycidyl-5, 5-dimethyl hydantoin has been used for primed steel plate to give a good coating for weathering, alkali, acid and water resistance<sup>28</sup>. Some thiohydantoin derivatives have been used in the treatment of blood circulation disorder<sup>29</sup>. Some thiohydantoin derivatives have been reported as inhibitors of pyrimidine biosynthesis<sup>30,5</sup>, 5-disubstituted thiohydantoin derivatives have also been synthesized for their anti HIV activity<sup>31</sup>. Synthesis of benzylidene derivatives of 3(2,3,4-chlorophenyl) thiohydantoin derivatives are reported for their anticonvulsant properties<sup>32</sup>, 1-bromo thiohydantoin derivatives is reported where transposition of halogen atom from nitrogen to 3-alkyl group is studied<sup>33</sup>. 1-N-phenyl substituted 2-thiohydantoin derivatives were synthesized by Z. Jinpei et al for their antinociceptive activity<sup>34</sup>. Acetylation of 3-substituted 1-amino-thiohydantoin derivatives has been reported<sup>35</sup>. Reaction of 5-arylidene-3-phenyl-2-thiohydantoin with 2,3,4,6-tetra-O-acetyl- $\alpha$ -D-glucopyranosyl bromide are reported. The product is arylidene-phenyl [(tetra acetyl glyco pyranosyl) thiohydantoin].<sup>36</sup> We now report a simple method for the preparation of 2-thiohydantoin derivatives that can easily be scaled up in the laboratory.

### EXPERIMENTAL:

The melting points were taken in a capillary tube; IR spectra were recorded in Nujol, <sup>1</sup>H NMR spectra were recorded in CDCl<sub>3</sub> with TMS as an internal standard. The purity of

A synthesized compound was checked by TLC. The structural elucidation of compound was done on the basis of chemical and spectral data. The starting ketones were 2-hydroxy-5-bromoacetophenone (II a), 2-hydroxy-3-nitro-5-bromoacetophenone (II b). 2-Hydroxy-5-bromoacetophenone (II a) was prepared from para bromo phenyl acetate (I a) by Fries migration using anhydrous  $\text{AlCl}_3$ . 2-Hydroxy-3-nitro-5-bromoacetophenone (II b) was prepared by nitration of 2-hydroxy-5-bromoacetophenone (II a).

Synthesized substituted acetophenone (II a&b) were condensed with substituted aldehyde separately to get corresponding chalcones (III a-d).

The above synthesized substituted chalcones (III a-d) were refluxed in DMSO medium in presence of mercuric acetate catalyst to yield 2-(substituted benzylidene)-7-substituted-5-bromocoumaran-3-one (IV a-d).

2-(substituted benzylidene)-7-substituted-5-bromocoumaran-3-one (IV a-d) was refluxed with thiourea in presence of alkaline medium and alcohol to get 2-substituted thiohydantoin (V a-d).

**Preparation of 5-(2-hydroxy-3-nitro-5-chlorophenyl) 5-(4-hydroxy-4-methoxybenzyl)-2-thiohydantoin (II a)**

2-(4' methoxy benzylidene)-5-bromo-7-nitrocoumaran-3-one (I a) (0.01 mole) and thiourea (0.01 mole) were dissolved in 40 ml of ethanol. To this mixture 10 ml of 10% KOH was added drop wise with constant stirring, allowed to stand for 2 to 3 hours. The reaction mixture was refluxed for 3 hrs. Cooled and then diluted with ice cold water washed several

times with 1%  $\text{NaHCO}_3$  solution and then with distilled water. It was then crystallized from ethanol to get 5-(2-hydroxy-3-nitro-5-chlorophenyl) 5-(4-hydroxy-4-methoxybenzyl)-2-thiohydantoin (II a).


The structure of compound (II a) has been supported by chemical and spectral data.

**Properties of the compound (II a)**

- Deep brown color crystalline solid m.p.  $128^\circ\text{C}$ .
- It shows positive ferric chloride indicating non-involvement of phenolic -OH group.
- An IR spectrum was recorded in Nijol.

- 3852 (-N-H, stretching).
- 3853 (-N-H, stretching).
- 3815-3801 (-OH group stretching).
- 1875 (Lactum cyclic C=S group stretching).
- 1511 (-NO<sub>2</sub> group symmetrical aromatic stretching).
- 1340 (-NO<sub>2</sub> group unsymmetrical aromatic stretching).
- 1251 (-NH bond stretching)
- 1060 (-CHOH group stretching).
- 1480  $\text{cm}^{-1}$  (C-Br group stretching).
- <sup>1</sup>H NMR in  $\text{CDCl}_3$  with TMS as an internal standard.
  - 1.25 (s, 1H, -CH).
  - 3.9 (s, 3H, Ar-OCH<sub>3</sub> group).
  - 6.3-6.4 (broad, 1H -OH).
  - 6.8 (m, 6H, Ar-H).
  - 6.9-7.86 (s, 1H, Ar-OH).

These chemical and spectral data shows that compound (II a) is got 5-(2-hydroxy-3-nitro-5-bromo phenyl) 5-(4-hydroxy-4-methoxy benzyl)-2-thiohydantoin. Similarly other compounds (II b-II d) were prepared by above method.



**Table 1: Synthesized compounds, M.P.'s and yields**

S. No.	Compounds	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	M. P. ( $^\circ\text{C}$ )	Yield (%)
1	II a	NO <sub>2</sub>	OCH <sub>3</sub>	H	H	126-128	76
2	II b	NO <sub>2</sub>	H	H	OH	124-1130	58
3	II c	H	H	H	H	143 -148	61
4	II d	H	H	NO <sub>2</sub>	H	156-160	71

**Biological assay of the synthesized products:**

The antimicrobial effects of thiohydantoin against clinically isolated microbes such as *Escherichia coli*, *Staphylococcus aureus*, *Klebsilla*, *Pseudomons* were studied. The technique used for this investigation was a disk-diffusion method on a nutrient agar medium. Sterilized nutrient agar was poured into Petri dish and allowed it to solidify. After solidification of the medium, a bacterial culture was spread over it uniformly with spreader. After it, a sterilized paper disc of size 4 mm immersed in

sample was inoculated on the medium with bacterial culture. This was done separately for different bacterial cultures. The plates were incubated overnight at 37°C to check the bacterial growth and drugs sensitivity (zone of inhibition). The area around disks that has no significant growth is referred to as the zone of inhibition. The zone of inhibition was observed on next day for different bacterial culture which was measured in mm. This experimental data was represented in the following table.




**Table 2: Antibacterial activity data of the heterocyclic derivatives of aurones**

Compound	<i>E. coli</i>	<i>S. aureus</i>	<i>Klebsiella</i>	<i>Pseudomons</i>
IIa	20.3 mm	12.7 mm	15.1 mm	18.2 mm
IIb	22.0 mm	14.8 mm	14.4 mm	14.0 mm
IIc	19.5 mm	20.0 mm	17.3 mm	18.8 mm
IId	18.3 mm	12.2 mm	16.0 mm	19.7 mm

The compound IIb showed maximum inhibitory activity of 22.0 mm one of inhibition for *E. coli* . Compounds IIb showed maximum inhibitory activity of 21.3 mm for *Klebsilla*. and Compound IId showed maximum inhibitory activity of 19.7 mm for ***Pseudomons*** and IIc showed maximum inhibitory activity of 19.5

and 20.0 mm for *S. aureus*; *E.coli*

The preliminary results of our study showed that substituted 2- thiohydantoin could serve as potential drug for preparation of pesticide and disinfectant. Further investigation are needed to anticonvulsants in the treatment of seizer disorder.



**REFERENCES:**

1. Johnson, T. B.; Chernoff, L. H. *J. Am. Chem. Soc.* **1913**, 35, 1208.
2. (a) Tompkins, J. E. *J. Med. Chem.* **1986**, 29, 855; (b) Elwood, J. C.; Richert, D. A.; Westerfeld, W.W. *Biochem. Pharmacol.* **1972**, 21, 1127.
3. Al-Obaid, A. M.; El-Subbagh, H. I.; Khodair, A. I.; Elmazar, M. M. *Anticancer Drugs* **1996**, 7, 873.
4. (a) Takahashi, A.; Matsuoka, H.; Ozawa, Y.; Uda, Y. *J. Agric. Food Chem.* **1998**, 46, 5037; (b) Froelich, E.; Fruehan, A.; Jackman, M.; Kirchner, F. K.; Alexander, E. J.; Archer, S. J. *Am. Chem. Soc.* **1954**, 76, 3099.
5. (a) Marx, J. V.; Richert, D. A.; Westerfeld, W. W. *J. Med. Chem.* **1970**, 13, 1179; (b) Chem. **2004**, 47, 681; (d) Yeh, W.-B.; Lin, M.-J.; Lee, M.-J.; Sun, C.-M. *Mol. Divers.* **2003**, 7, 185; (e) Erve, J. C. L.; Amarnath, V.; Sills, R. C.; Morgan, D. L.; Valentine, W. M. *Chem. Res. Toxicol.* **1998**, 11, 1128; (f) Marx, J. V.; Richert, D. A.; Westerfeld, W. W. *J. Med. Chem.* **1970**, 13, 1179; (g) Johnson, T.B.; Hill, A. J.; Kelsey, E. B. *J. Am. Chem. Soc.* **1920**, 42, 1711.
18. (a) Muccioli, G. G.; Martin, D.; Scriba, G. K. E.; Poppitz, W.; Poupaert, J. H.; Wouters, J.; Lambert, D. M. *J. Med. Chem.* **2005**, 48, 2509; (b) Muccioli, G. G.; Poupaert, J. H.; Wouters, J.; Norberg, B.; Poppitz, W.; Scriba, G. K. E.; Lambert, D. M. *Tetrahedron* **2003**, 59, 1301; (c) Muccioli, G. G.; Wouters, J.; Poupaert, J. H.; Norberg, B.; Poppitz, W.; Scriba, G. K. E.; Lambert, D. M. *Org. Lett.* **2003**, 5, 3599.
19. Mahmoud, A. M.; Abdel-Rahman, A. E.; El-Naggar, G. M.; El-Sherief, H. A. *Indian J. Chem. Sect. B* **1984**, 23B, 379.
20. Chain, E. B. *The Chemical Structure of the Penicillins*; Nobel Lecture, March 20, **1946**. Available at [http://nobelprize.org/nobel\\_prizes/medicine/laureates/1945/chain-lecture.pdf](http://nobelprize.org/nobel_prizes/medicine/laureates/1945/chain-lecture.pdf).
21. (a) Wang, X.-J.; Zhang, L.; Xu, Y. B.; Krishnamurthy, D.; Varsolona, R.; Nummy, L.; Shen, S.; Frutos, R. P.; Byrne, D.; Chung, J. C.; Farina, V.; Senanayake, C. H. *Tetrahedron Lett.* **2005**, 46, 273; (b) Nefzi, A.; Giulianotti, M. A.; Houghten, R. A. *Tetrahedron Lett.* **2000**, 41, 2283.
22. (a) Zhang, W.; Lu, Y. *Org. Lett.* **2003**, 5, 2555; (b) Zhang, W. *Tetrahedron*, **2003**, 59, 4475; (c) Gasch, C.; Salameh, B. A. B.; Pradera, M. A.; Fuentes, J. *Tetrahedron Lett.* **2001**, 42, 8615; (d) Somsák, L.; Nagy, V.; Docsa, T.; Tóth, B.; Gergely, P. *Tetrahedron: Asymmetr.* **2000**, 11, 405; (e) Floch, L.; Oremus, V.; Kovac, M. *Molecules* **1999**, 4, 279; (f) Morin, J. M.; Ternansky, R. J.; Noreen, R.; Lind, P. T. U. S. Pat. 5,714,503, **1998**; (g) Boyd, V. L.; Bozzini, M.; DeFranco, R. J. U. S. Pat. 5,665,603, **1997**; (h) Morin, J. M.; Ternansky, R. J.; Noreen, R.; Lind, P. T. U. S. Pat. 5,658,907, **1997**; (i) Sim, M. M.; Ganesan, A. J. *Org. Chem.* **1997**, 62, 3230. *Molecules* **2006**, 11 **750**
23. (a) Park, K. H.; Kurth, M. J. *J. Org. Chem.* **1999**, 64, 9297; (b) Karnbrock, W.; Deeg, M.; Gerhardt, J.; Rapp, W. *Mol. Divers.* **1998**, 4, 165; (c) Matthews, J.; Rivero, R. A. *J. Org. Chem.* **1997**, 62, 6090.
24. Kim, S. W.; Ahn, S. Y.; Koh, J. S.; Lee, J. H.; Ro, S.; Cho, H. Y. *Tetrahedron Lett.* **1997**, 38, 4603.
25. Ganesan, A. *Pure Appl. Chem.* **2001**, 73, 1033.
26. Schroder, Ludwig et al., *Eur. Pat. Appl. Ep.*, 91, 596, 19, Oct. (1983), DE. Appl. 3, 213140, 08 Apr. (1982), pp.47.
27. Bowness Garry W., Balbir S. et al. *J. Chem. Soc., Perkin, Trans-I*, (ii) (1983), 2649- 53 (ENG.).

28. Eisiac Co. Ltd. Jpn. Kokai Tokkyo Koho JP, 58, 213, 717 (83,213,717), (1983), Appl. 83/6085, 20 Jan 1982, 18.
29. Kurihara, Kenji, Kasahara et al., *Japan Kokai*, 78, 19, 348 (15336-81-9).
30. Kuron, Masatsune et al. Jpn. Kokai Tokkyo, Koho JP., 40,145,023, 05, (1990), 7.
31. Howie, Colin, 177 (1989), 189 (Eng.).
32. Comber, Robert N., Reynolds, *J. Med. Chem.*, **35(19)** (1992), Robert C., et al. 3567-72 (Eng.).
33. Rydzik, Elfryda, Kaminoka Anna, *Acta Pol. Pharm.*, **41(4)** (1984), 459-64 (Pol.).
34. Suarez A.R., Arguello B.V., *An. Asoc. Quim Argent.*, **72(5)** (1984), 493-9 (Eng.).
35. Zhou, Zinpei et al., *Zhongguo Yooke Dacue Auebao*, **22(6)** (1991), 330-3 (Ch.).
36. Ayupova A.T., Khim G.G., *Geterotsiki, Soedin*, **(ii)** (1991), 1512-14 (Russ.).
37. El-Barbary A.A., Saafan A.A. et al. *Delta J. Sci.*, **14(2)** (1990), 601-22 (Eng.).
38. Blanc M., Cussac M., *Eur. J. Med. Chem.*, **27(3)** (1992), Boucherie A., 267-75 (Fr.).
39. El-Barbary A.A., Saafan A.A. et al. *Delta J. Sci.*, **14(2)** (1990), 623-46 (Eng.).
40. Aboutabi M.A., Abdel Rehmoan, *J. Chem. Technol. Biotechnol. Chem. Technol.*, **33A(6)** (1983), 286-93 (Eng.).

\*\*\*\*\*